AVROBIO receives orphan drug designation from European Medicines Agency for AVR-RD-02

This article was originally published here

AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. AVROBIO recently dosed the first

The post AVROBIO receives orphan drug designation from European Medicines Agency for AVR-RD-02 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply